Immunotherapy targeting the programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint has been developed and is widely used in cancer therapy, including for NSCLC [12,13]. Here, PDCD1 is linked to non-small cell lung carcinoma.